DelNova Selected to Present at the 2019 Start-Up Stadium during BIO 2019
Presentation to highlight ReViVox™, DelNova's lead product candidate designed for treating complications resulting from undesirable muscle paralysis following botulinum neurotoxin (e.g. Botox®) procedures SAN DIEGO and CHICAGO, May 29, 2019 /PRNewswire/ -- DelNova, a biopharmaceutical company developing clinically validated molecules linked to advances in drug delivery, announced today that its...
29 May, 2019
/ 0 Comments